Levi & Korsinsky, LLP
CLASS ACTION UPDATE for PRVB, FREQ and YMM: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / July 20, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
PRVB Shareholders Click Here: https://www.zlk.com/pslra-1/provention-bio-inc-loss-submission-form?prid=17819&wire=1
FREQ Shareholders Click Here: https://www.zlk.com/pslra-1/frequency-therapeutics-inc-loss-submission-form?prid=17819&wire=1
YMM Shareholders Click Here: https://www.zlk.com/pslra-1/full-truck-alliance-co-ltd-information-request-form?prid=17819&wire=1
* ADDITIONAL INFORMATION BELOW *To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
Provention Bio, Inc. (NASDAQ:PRVB)
PRVB Lawsuit on behalf of: investors who purchased November 2, 2020 - April 8, 2021
Lead Plaintiff Deadline : July 20, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/provention-bio-inc-loss-submission-form?prid=17819&wire=1
According to the filed complaint, during the class period, Provention Bio, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the teplizumab Biologics License Application ("BLA") was deficient in its submitted form and would require additional data to secure U.S. Food and Drug Administration approval; (ii) accordingly, the teplizumab BLA lacked the evidentiary support the Company had led investors to believe it possessed; (iii) the Company had thus overstated the teplizumab BLA's approval prospects and hence the commercialization timeline for teplizumab; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Frequency Therapeutics, Inc. (NASDAQ:FREQ)
FREQ Lawsuit on behalf of: investors who purchased November 16, 2020 - March 22, 2021
Lead Plaintiff Deadline : August 2, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/frequency-therapeutics-inc-loss-submission-form?prid=17819&wire=1
According to the filed complaint, during the class period, Frequency Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: the Company's Phase 2a trial results failed to live up to the Company's expectations as the results revealed no discernable difference between FX-322 and the placebo. In spite of the disappointing results, the Company continued to conduct the Phase 2a study while releasing positive statements in earnings calls, press releases, SEC filings, and pharmaceutical presentations about FX-322's potential. These statements materially misled the market and artificially inflated the value of Frequency's common stock.
Full Truck Alliance Co. Ltd. (NYSE:YMM)
This lawsuit is on behalf of persons who purchased or otherwise acquired Full Truck's securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with Full Truck's June 2021 initial public offering.
Lead Plaintiff Deadline : September 10, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/full-truck-alliance-co-ltd-information-request-form?prid=17819&wire=1
According to the filed complaint, (1) Full Truck's apps Yunmanman and Huochebang would face an imminent cybersecurity review by the Chinese government; (2) the Chinese government would require Full Truck to suspend new user registration; (3) FTA needed to conduct a "comprehensive self-examination of any cybersecurity risks"; (4) Full Truck needed to "continue to improve its cybersecurity systems and technology capabilities"; and (5) as a result, Defendants' public statements were materially false and misleading at all relevant times and negligently prepared.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com:
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
Subscribe to releases from ACCESSWIRE
Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESSWIRE
Smart Eye25.11.2021 15:09:03 CET | Press release
Smart Eye completes the acquisition of iMotions
Bambuser AB25.11.2021 14:43:21 CET | Press release
BuzzFeed Taps Bambuser to Create Live Video Shopping Initiatives
STRAX25.11.2021 09:06:51 CET | Press release
Interim Report no. 3 for Financial Year 2021
BioInvent International25.11.2021 08:51:35 CET | Press release
Nomination Committee Appointed for BioInvent International’s Annual General Meeting 2022
Adverty AB25.11.2021 08:21:29 CET | Press release
Adverty Partners With Smart to Further Facilitate Access to Its Seamless in-Game Inventory
TECO 2030 ASA25.11.2021 07:01:35 CET | Press release
TECO 2030 is Leading a Project Group That Will Build A Hydrogen-Powered High-Speed Vessel For The Port of Narvik
Prospera Energy Inc.24.11.2021 14:31:51 CET | Press release
Prospera Energy Inc. Announces the Launch of New Website
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom